SURMOUNT-1

Study record

Population

2,539 adults; BMI ≥30, or ≥27 with a weight-related complication; diabetes excluded.

Formulation

Tirzepatide versus placebo; preparation details not extracted.

Route

Subcutaneous injection

Dose & frequency

Assigned maintenance arms: 5, 10, or 15 mg once weekly. Not starting doses; escalation included.

Study design

Phase 3; randomized, double-blind, placebo-controlled.

Duration

72 weeks, including 20 weeks of dose escalation.

Reported findings

Mean weight change: −15.0%, −19.5%, −20.9% across ascending dose arms; placebo −3.1%.

Adverse events

Gastrointestinal events predominated. Discontinuation for adverse events: 4.3–7.1% across tirzepatide arms; placebo 2.6%.